1. Home
  2. Companies
  3. NOX
  4. Material Events

Noxopharm (ASX:NOX) — Material Events

ASX:NOX · 21 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 15 articles Notable 6 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
15
Noxopharm’s Sofra Platform Amplifies TLR8 Immune Response Over 200-FoldMedium
Noxopharm's Sofra platform shows strong TLR8 immune activation, advancing cancer immunotherapy
26 May 2026 ·Research Data Update ·85
Noxopharm’s Sofra™ Science Breakthrough Published in Nature ImmunologyMedium
Noxopharm's Sofra™ breakthrough science published in Nature Immunology, advancing autoimmune disease therapeutics
11 Feb 2026 ·Research Publication Announcement ·85
Noxopharm Secures First US Patent for Breakthrough Cancer ImmunotherapyMedium
Noxopharm awarded first US patent for Sofra™ cancer immunotherapy platform
22 Oct 2025 ·Patent Grant Announcement ·80
Noxopharm’s SOF-16 Shows Strong Anti-Inflammatory Effects in Lupus and Arthritis SamplesMedium
Noxopharm's SOF-16 shows potent anti-inflammatory effects in lupus and rheumatoid arthritis patient samples
1 May 2026 ·Research Data Release ·80
Noxopharm Clears Safety Hurdle in HERACLES Trial, Eyes Phase II ProgressMedium
Noxopharm completes HERACLES trial dosing with positive safety, secures new partnership and patent, explores funding options
30 Jan 2026 ·Quarterly Activities Report and Appendix 4C ·80
Noxopharm Launches HERACLES Trial, Expands Sofra Collaborations Amid Funding PushMedium
Noxopharm launches HERACLES trial, expands Sofra collaborations, seeks funding
30 July 2025 ·Quarterly Activities Report and Appendix 4C ·80
Noxopharm Advances Sofra Platform with New CEO and Key CollaborationsMedium
Noxopharm signs MoU with Tezcat, publishes key Sofra research, appoints new CEO, reports positive trial and cash flow
24 Apr 2026 ·Quarterly Activities Report and Appendix 4C ·80
Noxopharm Expands Sofra Platform with New Collaborations and Positive Trial Safety DataMedium
Noxopharm advances Sofra platform with new collaborations, positive HERACLES trial update, and funding extension
30 Oct 2025 ·Quarterly Activities Report and Appendix 4C ·75
Noxopharm Clears Safety Hurdle in HERACLES Trial, Eyes Phase II LaunchMedium
Noxopharm completes HERACLES trial with positive safety results, advancing to Phase II studies
21 Jan 2026 ·Clinical Trial Update ·75
Noxopharm Advances HERACLES Trial, Clears Third SOF-SKN™ Dose SafelyMedium
Noxopharm completes third dose cohort in HERACLES trial, progressing to highest SOF-SKN™ dose
25 Aug 2025 ·Clinical Trial Update ·75
Noxopharm Engages Novotech to Advance SOF-SKN US FDA StrategyMedium
Noxopharm advances US FDA regulatory strategy for SOF-SKN with Novotech engagement
6 May 2026 ·Regulatory Update ·75
Noxopharm and InhaTarget Demonstrate 77% Lung Inflammation Reduction with Sofra InhalationMedium
Noxopharm and InhaTarget report strong lung inflammation reduction using Sofra™ inhalation delivery
27 Apr 2026 ·Collaboration Update ·75
Noxopharm’s SOF-SKN Shows Multi-Day Skin Retention, Boosting Cutaneous Lupus ProspectsMedium
Noxopharm reports promising SOF-SKN dosing data showing prolonged skin retention and minimal systemic absorption
22 Apr 2026 ·Clinical Trial Update ·75
Noxopharm Advances SOF-SKN™ Trial with Safe Second Dose CompletionMedium
Noxopharm completes second dose cohort in SOF-SKN™ HERACLES trial, advancing to higher dose
11 Aug 2025 ·Clinical Trial Update ·75
Noxopharm and Tezcat Biosciences Unlock New Potential for Sofra™ Drug DeliveryMedium
Noxopharm and Tezcat Biosciences report promising Sofra™ drug delivery results, advancing collaboration
5 Aug 2025 ·Collaboration Update ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.